P anca test significance in dermatology

Reading File
Finding Sources
Finding Sources
Searching PubMed

p-ANCA dermatology skin manifestations

Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive information to provide a detailed, well-structured answer. Here it is:

P-ANCA (Perinuclear ANCA): Significance in Dermatology

What is P-ANCA?

Antineutrophil cytoplasmic antibodies (ANCAs) are autoantibodies directed against antigens in the cytoplasm of neutrophils. On indirect immunofluorescence (IIF), they produce two main patterns:
PatternTarget AntigenIIF Appearance
c-ANCAProteinase 3 (PR3)Cytoplasmic, granular
p-ANCAMyeloperoxidase (MPO)Perinuclear
Atypical ANCANeither PR3 nor MPOAtypical
Important: The specificity of the p-ANCA pattern alone is low. Anti-MPO antibodies confirmed by ELISA are required to make p-ANCA clinically meaningful for diagnosing vasculitis. A 2017 international consensus recommends high-quality immunoassays for PR3 and MPO without needing IIF as the initial screen.

ANCA-Associated Vasculitides (AAV) with Dermatological Relevance

The three primary ANCA-associated vasculitides (AAVs) are MPA, GPA, and EGPA. When used appropriately, ANCA testing achieves 85% sensitivity and 98% specificity for these conditions.
Range of Frequencies of ANCA in ANCA-Associated Vasculitides
ANCA frequencies across AAVs — p-ANCA/MPO-ANCA dominates in MPA and drug-induced vasculitis (Dermatology, 5th ed.)

1. Microscopic Polyangiitis (MPA) — p-ANCA is the dominant pattern

  • ANCA positivity: ~70% positive; p-ANCA (anti-MPO) more frequent than c-ANCA
  • Skin involved in 44% — the skin may be the initial presenting feature
  • Cutaneous findings:
    • Purpuric papules and macules (most common)
    • Livedo reticularis (in ~2/3 of those with skin-first presentation)
    • Retiform purpura, cutaneous ulcers, digital ischemia
    • Necrotizing leukocytoclastic vasculitis (LCV) in reticular dermis on biopsy
  • Systemic: glomerulonephritis (80–90%), pulmonary capillaritis, vasculitic neuropathy (58%)
  • Distinguishing feature from PAN: presence of GN, pulmonary symptoms; ANCA rarely positive in PAN

2. Granulomatosis with Polyangiitis (GPA) — c-ANCA dominant, but ~10% have p-ANCA

  • ANCA positivity: ~90% in active generalized disease
    • ~90% are c-ANCA (anti-PR3); the remainder are p-ANCA (anti-MPO)
  • Skin involved in ~1/3 of patients at presentation; cutaneous involvement is a risk marker for severe systemic disease (GN, alveolar hemorrhage)
  • Cutaneous findings:
    • Purpuric papules/macules, petechiae
    • Papulonecrotic lesions (especially extensor surfaces, elbows)
    • Subcutaneous nodules, ulcerations resembling pyoderma gangrenosum
    • "Strawberry gums" — hypertrophic gingivitis, characteristic and biopsy-accessible
    • Saddle-nose deformity, nasal septal perforation (mucosal involvement)
    • Livedo reticularis is rare in GPA
  • Histology: LCV ± granulomatous inflammation; palisaded granulomas with multinucleated giant cells

3. Eosinophilic Granulomatosis with Polyangiitis (EGPA / Churg-Strauss)

  • ANCA positivity: ~40–50%; predominantly p-ANCA (anti-MPO)
  • Associated with asthma, peripheral eosinophilia (>1000 cells/μL) — helps differentiate from asthma/atopy
  • Skin: purpura, papulonecrotic nodules ("Churg-Strauss nodules"), subcutaneous nodules

P-ANCA in Drug-Induced Vasculitis — Critical Dermatological Context

This is one of the most practically important applications:
  • Drugs causing p-ANCA/MPO-ANCA-positive vasculitis:
    • Propylthiouracil (PTU)
    • Minocycline
    • Hydralazine
    • Allopurinol, sulfonamides, gold, thiazides, phenytoin
  • Key clue: Both c-ANCA AND p-ANCA positive simultaneously → suspect drug-induced vasculitis, including levamisole-tainted cocaine
  • Levamisole-adulterated cocaine (present in up to 70% of U.S. seized cocaine):
    • Produces ecchymotic purpura/necrosis with predilection for ears, nose, thighs, buttocks
    • Both c-ANCA and p-ANCA can be elevated
    • c-ANCA reacts with human neutrophil elastase (HNE-ANCA) — patients with true GPA/MPA are HNE-ANCA negative — useful distinguishing test
    • Also causes agranulocytosis (atypical for true AAV)

P-ANCA in Non-Vasculitic Dermatological Conditions

The p-ANCA pattern (without MPO specificity) can be found as a false-positive or non-specific finding in:
ConditionNotes
Inflammatory bowel disease (IBD)Atypical ANCA common in UC; does not indicate vasculitis
SLECan present with cutaneous vasculitis; ANCA testing part of pulmonary-renal workup
Rheumatoid arthritisLow-titer, usually non-MPO specific
CryoglobulinemiaPositive ANCAs can be found
Skin-limited vasculitisAnnual incidence of underlying AAV ~4 per million in biopsy-proven cutaneous small-vessel vasculitis (~10%)
Infectious diseasesTB, endocarditis, HIV

Diagnostic Algorithm for Dermatologists

Skin vasculitis suspected
       ↓
Screen: IIF for ANCA pattern
       ↓
Positive p-ANCA pattern
       ↓
Confirm with ELISA: Anti-MPO antibody?
   ├─ YES → Strongly suggests MPA, EGPA, or drug-induced AAV
   │         Assess: renal function, pulmonary symptoms, drug history
   └─ NO  → Atypical ANCA — consider IBD, SLE, infection
              (low specificity for primary vasculitis)

Key Takeaways

  1. p-ANCA alone (by IIF) has low specificity — MPO confirmation by ELISA is essential
  2. p-ANCA/MPO-ANCA is the hallmark of MPA, and skin is involved in nearly half of MPA cases — often as the presenting feature
  3. ~10% of GPA patients have p-ANCA (not c-ANCA); these must be distinguished from MPA
  4. Dual positivity (p-ANCA + c-ANCA) should always raise suspicion for drug-induced vasculitis or levamisole-cocaine exposure
  5. HNE-ANCA is a useful differentiator: positive in cocaine/levamisole vasculitis, negative in true GPA/MPA
  6. ANCA testing does not replace clinical evaluation, histopathology, and organ-specific investigations
  7. ANCA positivity in skin-limited vasculitis warrants systemic workup (renal, pulmonary), since AAV underlies ~10% of such cases

Sources: Andrews' Diseases of the Skin, 13th ed.; Dermatology, 5th ed. (Elsevier); Fitzpatrick's Dermatology, 9th ed.
This is a shared conversation. Sign in to Orris to start your own chat.